Quanterix Overview
- Year Founded
-
2007

- Status
-
Public
- Employees
-
370

- Stock Symbol
-
QTRX

- Investments
-
2
- Share Price
-
$23.04
- (As of Friday Closing)
Quanterix General Information
Description
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum and other fluids which are undetectable using conventional, analog immunoassay technologies. The company has developed Simoa technology which is a method of detection of proteins and has the capability of analyzing nearly six biomarkers per test, with anticipated expansion capability.
Contact Information
- 900 Middlesex Turnpike
- Building 1
- Billerica, MA 01821
- United States
Quanterix Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$23.04 | $22.75 | $10.02 - $28.77 | $861M | 37.8M | 379K | -$1.03 |
Quanterix Financials Summary
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
---|---|---|---|---|
EV | 733,016 | 212,428 | 1,167,341 | 1,330,385 |
Revenue | 115,553 | 104,952 | 105,339 | 79,955 |
EBITDA | (46,257) | (96,417) | (52,470) | (27,321) |
Net Income | (38,506) | (96,700) | (57,688) | (31,530) |
Total Assets | 429,042 | 434,199 | 501,527 | 271,045 |
Total Debt | 42,399 | 44,104 | 21,892 | 30,798 |
Quanterix Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Quanterix Comparisons
Industry
Financing
Details
Quanterix Competitors (20)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Cepheid | Formerly VC-backed | Sunnyvale, CA | 0000 | 000.00 | 0000000000 | |
0000000 0000000000 | Corporation | Forchheim, Germany | 00000 | 00.000 | 000000000 | 00.000 |
00 0000000000 | Formerly VC-backed | Lexington, MA | 000 | 00000 | 00000000000 | 00000 |
000000000 | Venture Capital-Backed | New Richmond, WI | 00 | 000.00 | 000000 - 000 | 000.00 |
00000000 000000000 | Venture Capital-Backed | Richmond, VA | 00 | 000.00 | 00000000000 | 000.00 |
Quanterix Patents
Quanterix Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220205992-A1 | Materials and kits relating to association of reporter species and targeting entities with beads | Pending | 28-Dec-2020 | 000000000000 | 0 |
US-20220050106-A1 | Methods and kits for detecting sars-coronavirus-2 antigen | Pending | 14-Aug-2020 | 000000000000 | |
US-20210341479-A1 | Quantitative antibody test | Active | 30-Apr-2020 | 000000000000 | 0 |
US-11686730-B2 | Quantitative antibody test | Active | 30-Apr-2020 | 000000000000 | 00 |
EP-4135897-A2 | Methods and systems related to highly sensitive, digital assays by improved delivery of capture objects | Pending | 15-Apr-2020 | G01N33/54386 |
Quanterix Executive Team (25)
Quanterix Board Members (18)
Name | Representing | Role | Since |
---|---|---|---|
00000 000000 | Quanterix | Board Member | 000 0000 |
00000 0000 00.0 | Self | Board Member & Founder | 000 0000 |
00000 00000 | Self | Board Member | 000 0000 |
00000 00000000 | ARCH Venture Partners | Board Member | 000 0000 |
000000 00000 | Quanterix | Board Member | 000 0000 |
Quanterix Signals
Quanterix Acquisitions (2)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
UmanDiagnostics | 01-Aug-2019 | 0000000000 | 000.00 | Diagnostic Equipment | 00000 000 |
Aushon BioSystems | 30-Jan-2018 | Merger/Acquisition | 000 | Discovery Tools (Healthcare) | 00000 000 |
Quanterix Subsidiaries (1)
Company Name | Industry | Location | Founded |
---|---|---|---|
UmanDiagnostics | Diagnostic Equipment | Umea, Sweden | 0000 |
Quanterix ESG
Risk Overview
Risk Rating
Updated January, 10, 2023
20.25 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,708
Rank
Percentile

Pharmaceuticals
Industry
00 of 884
Rank
Percentile

Laboratory Equipment and Services
Subindustry
00 of 67
Rank
Percentile
